Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 8/20 | 0.73 |
| ▸ | THRA | P10827 | 7/20 | 0.73 |
| ▸ | PPARG | P37231 | 5/20 | 0.73 |
| ▸ | RXRA | P19793 | 3/20 | 0.73 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.73 |
| ▸ | ITGAV | P06756 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | TTR | P02766 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | HTR1A | P08908 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | HTR2B | P41595 | 2/20 | 0.57 |
| ▸ | PGR | P06401 | 2/20 | 0.57 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14485394 | 0.87 | HSP90AB1 (0.66) | THRBTHRAPPARGRXRAITGB3 | |
| SCHEMBL5741869 | 0.85 | PCNA (0.62) | THRBTHRAPPARGRXRAITGB3 | |
| SCHEMBL13949709 | 0.84 | THRB (0.77) | THRBTHRAPPARGRXRAITGB3 | |
| Tetrac SCHEMBL365951 | 0.84 | THRB (1.00) | THRBTHRAPPARGRXRAITGB3 | |
| SCHEMBL1526094 | 0.84 | THRB (0.68) | THRBTHRAPPARGRXRAITGB3 | |
| SCHEMBL6857392 | 0.84 | THRB (0.52) | THRBTHRAPPARGRXRAITGB3 | |
| SCHEMBL5742498 | 0.84 | PCNA (0.53) | THRBTHRAPPARGRXRAITGB3 | |
| SCHEMBL19677574 | 0.83 | THRB (0.51) | THRBTHRAPPARGRXRAITGB3 | |
| SCHEMBL6852102 | 0.83 | THRB (0.51) | THRBTHRAPPARGRXRAITGB3 | |
| SCHEMBL1694507 | 0.81 | THRB (0.63) | THRBTHRAPPARGRXRAITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351137-B2 | Composition and method for dual targeting in treatment of neuroendocrine tumors | NANOPHARMACEUTICALS LLC (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210299262-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | NANOPHARMACEUTICALS LLC | 2021-09-30 | — | — | US | disclosed |
| US-10695436-B2 | Non-cleavable polymer conjugated with alpha V beta 3 integrin thyroid antagonists | NANOPHARMACEUTICALS, LLC (US) | 2020-06-30 | — | — | US | disclosed |
| US-10695436-B2 | Non-cleavable polymer conjugated with alpha V beta 3 integrin thyroid antagonists | NANOPHARMACEUTICALS, LLC (US) | 2020-06-30 | — | — | US | disclosed |
| EP-2442800-B1 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE, ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | NANOPHARMACEUTICALS LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20190111145-A1 | NON-CLEAVABLE POLYMER CONJUGATED WITH ALPHA V BETA 3 INTEGRIN THYROID ANTAGONISTS | NANOPHARMACEUTICALS, LLC | 2019-04-18 | — | — | US | disclosed |
| US-20190111145-A1 | NON-CLEAVABLE POLYMER CONJUGATED WITH ALPHA V BETA 3 INTEGRIN THYROID ANTAGONISTS | NANOPHARMACEUTICALS, LLC | 2019-04-18 | — | — | US | disclosed |
| EP-3463477-A1 | NON-CLEAVABLE POLYMER CONJUGATED WITH avß3 INTEGRIN THYROID ANTAGONISTS | NanoPharmaceuticals LLC (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10201616-B2 | Non-cleavable polymer conjugated with αVβ3 integrin thyroid antagonists | NANOPHARMACEUTICALS, LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-10201616-B2 | Non-cleavable polymer conjugated with αVβ3 integrin thyroid antagonists | NANOPHARMACEUTICALS, LLC (US) | 2019-02-12 | — | — | US | disclosed |
| EP-2662079-A1 | Uses of formulations of thyroid hormone antagonists and nanoparticulate forms thereof to increase chemosensivity and radiosensitivity in tumor or cancer cells | Ordway Research Institute, Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| EP-2662079-A1 | Uses of formulations of thyroid hormone antagonists and nanoparticulate forms thereof to increase chemosensivity and radiosensitivity in tumor or cancer cells | Ordway Research Institute, Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| US-20120315320-A1 | USES OF FORMULATIONS OF THYROID HORMONE ANALOGS AND NANOPARTICULATE FORMS THEREOF TO INCREASE CHEMOSENSIVITY AND RADIOSENSITIVITY IN TUMOR OR CANCER CELLS | NANOPHARMACEUTICALS LLC | 2012-12-13 | — | — | US | disclosed |
| US-20120315320-A1 | USES OF FORMULATIONS OF THYROID HORMONE ANALOGS AND NANOPARTICULATE FORMS THEREOF TO INCREASE CHEMOSENSIVITY AND RADIOSENSITIVITY IN TUMOR OR CANCER CELLS | NANOPHARMACEUTICALS LLC | 2012-12-13 | — | — | US | disclosed |
| EP-2442800-A2 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE, ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | Ordway Research Institute, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20110105482-A1 | COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS | VASCULAR VISION PHARMACEUTICAL COMPANY (US) | 2011-05-05 | — | — | US | disclosed |
| WO-2010148007-A9 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE, ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | ORDWAY RESEARCH INSTITUTE, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20110052715-A1 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | NANOPHARMACEUTICALS LLC | 2011-03-03 | — | — | US | disclosed |
| US-20110052715-A1 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | NANOPHARMACEUTICALS LLC | 2011-03-03 | — | — | US | disclosed |
| WO-2010148007-A2 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE, ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | ORDWAY RESEARCH INSTITUTE, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10201616-B2 | Non-cleavable polymer conjugated with αVβ3 integrin thyroid antagonists | CD44, THRA, TSHR | THRB 6/4885THRA 2/4885PPARG 955/4885 |
| US-20110105482-A1 | COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS | TEK, THRA, TSHR | THRB 4/4885THRA 2/4885PPARG 449/4885 |
| US-20190111145-A1 | NON-CLEAVABLE POLYMER CONJUGATED WITH ALPHA V BETA 3 INTEGRIN THYROID ANTAGONISTS | THRA, CD44, ITGAV | THRB 5/4885THRA 1/4885PPARG 861/4885 |
| US-10695436-B2 | Non-cleavable polymer conjugated with alpha V beta 3 integrin thyroid antagonists | THRA, CD44, ITGAV | THRB 5/4885THRA 1/4885PPARG 861/4885 |
| US-20120315320-A1 | USES OF FORMULATIONS OF THYROID HORMONE ANALOGS AND NANOPARTICULATE FORMS THEREOF TO INCREASE CHEMOSENSIVITY AND RADIOSENSITIVITY IN TUMOR OR CANCER CELLS | TSHR, TPO, THRA | THRB 5/4885THRA 3/4885PPARG 317/4885 |
| US-11351137-B2 | Composition and method for dual targeting in treatment of neuroendocrine tumors | THRB, TSHR, SLC6A2 | THRB 1/4885THRA 4/4885PPARG 1620/4885 |
| US-20110052715-A1 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | TSHR, THRA, TRHR | THRB 4/4885THRA 2/4885PPARG 145/4885 |
| US-20210299262-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | THRB, TSHR, SLC6A2 | THRB 1/4885THRA 4/4885PPARG 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.